Indication
As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.
Medicine details
- Medicine name:
- cemiplimab (Libtayo)
- SMC ID:
- SMC2584
- Pharmaceutical company
- Sanofi
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Reassessment
- Publication due date:
- 11 December 2023
- SMC meeting date:
- 07 November 2023
- Patient group submission deadline:
- 04 September 2023